(SLRN) ACELYRIN Common Stock - Ratings and Ratios

Acelyrin, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, acquisition, and accelerated development of innovative therapies aimed at addressing significant unmet medical needs. The companys lead product candidate, izokibep, is a potent, small protein therapeutic designed to inhibit interleukin-17A (IL-17A), a cytokine implicated in various inflammatory conditions. Currently, izokibep is in Phase 3 clinical trials for the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, while also being evaluated in Phase 2 trials for Axial Spondyloarthritis. This versatile therapeutic approach underscores Acelyrins commitment to tackling a range of immune-mediated and inflammatory diseases.

Beyond izokibep, Acelyrins pipeline includes lonigutamab, a humanized IgG1 monoclonal antibody targeting the CD40 ligand, currently in Phase 1 clinical trials for the treatment of thyroid eye disease, a condition often associated with Graves disease. Additionally, the company is advancing SLRN-517, a fully human IgG1 monoclonal antibody targeting the c-KIT receptor, which is in preclinical development for the treatment of chronic urticaria. These diverse therapeutic candidates highlight Acelyrins strategic focus on immune-mediated and inflammatory disorders.

Acelyrin, Inc., established in 2020 and headquartered in Agoura Hills, California, operates with a lean, asset-centric business model, emphasizing the rapid progression of promising therapies through clinical development. The companys approach is characterized by a disciplined focus on transformative medicines, aiming to deliver significant value to patients and stakeholders alike.

Ticker Symbol: SLRN Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology Average Volume 20d: 3,768,182 Last Price: 2.68 SMA 20: 2.19 SMA 50: 2.45 SMA 200: 4.34 ATR: 0.21 Market Cap: 256.83M USD P/E: 0.00 P/E Forward: 0.00 P/B: 0.49 P/S: 0.00 RoE: -50.05 3-Month Forecast: - Technical Outlook: SLRNs stock price is below its SMA 20 and SMA 50, indicating bearish momentum. The SMA 200 is significantly higher, suggesting a potential long-term downtrend. ATR remains stable, indicating moderate volatility. - Fundamental Outlook: With a market cap of $256.83M and a P/B ratio of 0.49, SLRN is positioned as a mid-sized biotech firm with potential undervaluation. The negative RoE of -50.05% reflects ongoing developmental losses, typical for early-stage biotech companies, but raises concerns about profitability timelines. Projections: 1. Price Movement: Expect continued volatility with potential downside risks, supported by the bearish SMA trend and lack of positive earnings indicators. 2. Volume: Average volume is expected to remain steady, with possible spikes during earnings or clinical trial updates. 3. Catalysts: Upcoming data readouts for izokibep and lonigutamab could serve as key catalysts, influencing short-term price movements. Risks: - Clinical Development: Negative trial results could significantly impact valuation. - Financial Health: Ongoing losses may pressure the company to seek additional financing, potentially diluting shareholder value. - Market Sentiment: Biotech sector volatility could influence SLRNs stock price independently of company-specific developments.